Related Experiment Video
Updated: Oct 1, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes
Stephen R Plymate1,2, Cynthia Sprenger1, Michael C Haffner3,4,5
1Department of Medicine, University of Washington, Seattle, WA, USA.
Abstract:
Metastatic prostate cancer remains uncurable. In this issue of Cell Reports Medicine, Rice et al. present an assessment of a compound (SU086) demonstrating activity in prostate cancer models through heat shock protein 90 inhibition and cell metabolism changes.
Insights
A new compound, SU086, shows promise against metastatic prostate cancer by targeting heat shock protein 90 and altering cell metabolism. This research offers a potential new avenue for treating this incurable disease.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Research
Background:
- Metastatic prostate cancer is a significant clinical challenge with limited treatment options.
- Heat shock protein 90 (HSP90) is implicated in cancer cell survival and proliferation.
- Altering cellular metabolism is a key strategy in cancer therapy development.
Discussion:
- The compound SU086 targets heat shock protein 90 (HSP90) in prostate cancer models.
- SU086 induces significant changes in cancer cell metabolism.
- These dual mechanisms suggest a novel therapeutic approach.
Key Insights:
- SU086 demonstrates anti-cancer activity in preclinical prostate cancer models.
- Inhibition of HSP90 by SU086 leads to metabolic reprogramming in cancer cells.
- The study provides a mechanistic understanding of SU086's action.
Outlook:
- Further investigation of SU086 is warranted for potential clinical translation.
- Targeting HSP90 and cellular metabolism represents a promising strategy for prostate cancer treatment.
- This research could pave the way for new therapies against advanced prostate cancer.
